avapro has been researched along with Diabetic Glomerulosclerosis in 149 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 8.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "The present study assessed the cost effectiveness of irbesartan, an angiotensin II receptor antagonist, and amlodipine, a calcium channel blocker, in the treatment of Canadian patients with diabetic nephropathy and hypertension." | 7.72 | Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. ( Coyle, D; Rodby, RA, 2004) |
| "Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide." | 6.45 | Rational of the use of aliskiren in hypertension and beyond. ( Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D, 2009) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 6.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| " Using treatment-specific probabilities derived from the Irbesartan in Diabetic Nephropathy Trial (IDNT), the cost effectiveness of treating patients with hypertension, type II diabetes and nephropathy with irbesartan, amlodipine or control was calculated using a Markov model." | 5.11 | An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. ( Annemans, L; Bilous, RW; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| " Inclusion criteria were type 2 diabetes, hypertension > 140/90 mmHg and current treatment with irbesartan or irbesartan/hydrochlorothiazide (HTCZ)." | 5.11 | [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. ( Krekler, M; Schmieder, RE, 2005) |
| "Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial." | 5.11 | Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005) |
| "There is an incremental clinical benefit of irbesartan over losartan in the treatment of hypertension and diabetic nephropathy which can be substantiated by corresponding preclinical study evidence." | 4.86 | Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan. ( Bramlage, P; Schindler, C, 2010) |
| "Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension." | 4.84 | Irbesartan: a review of its use in hypertension and diabetic nephropathy. ( Croom, KF; Plosker, GL, 2008) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 4.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia." | 4.82 | Outcome studies in diabetic nephropathy. ( Mohanram, A; Toto, RD, 2003) |
| "Irbesartan (Avapro, Aprovel) is a potent and selective angiotensin II subtype 1 receptor antagonist indicated for use in patients with hypertension, including those with type 2 diabetes mellitus and nephropathy." | 4.82 | Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. ( Croom, KF; Curran, MP; Goa, KL; Perry, CM, 2004) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "Hypertension is a major risk factor for renal disease and is common in people with diabetes mellitus." | 3.78 | Renoprotection and renin-angiotensin system blockade in diabetes mellitus. ( Ruilope, LM, 1997) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | 3.73 | [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| "The present study assessed the cost effectiveness of irbesartan, an angiotensin II receptor antagonist, and amlodipine, a calcium channel blocker, in the treatment of Canadian patients with diabetic nephropathy and hypertension." | 3.72 | Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. ( Coyle, D; Rodby, RA, 2004) |
| "We estimated the cost-effectiveness of irbesartan compared with placebo or amlodipine in the treatment of patients with type 2 diabetes mellitus, hypertension, and overt nephropathy." | 3.72 | The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. ( Annemans, L; Borenstein, J; Chen, RS; Chiou, CF; Lewis, EJ; Palmer, AJ; Rodby, RA; Roze, S; Sengupta, N; Simon, TA; Smitten, A, 2003) |
| "The "Irbesartan in Diabetic Nephropathy Trial" (IDNT), demonstrated a reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease (ESRD) or death compared to control or amlodipine arms in patients with hypertension, type 2 diabetes and overt nephropathy when treated with irbesartan." | 3.72 | [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "There is a lack of research on the effect of low dose of angiotensin receptor blockers combined with spironolactone, and the effect of high dose of angiotensin receptor blockers alone on the urinary albumin excretion rate (UAER) in elderly patients with early type 2 diabetic nephropathy (DN)." | 2.87 | Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. ( Chen, X; Chen, Y; Li, Y; Liu, P; Wang, Y; Zhang, F, 2018) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "2,739 participants with type 2 diabetes and nephropathy with at least 1 year of blood pressure measurements available." | 2.79 | Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. ( de Zeeuw, D; Dwyer, JP; Forman, JP; Lambers Heerspink, HJ; McMullan, CJ; Parving, HH, 2014) |
| "A total of 45 type 2 diabetic kidney disease patients were enrolled into this prospective study, and were randomly divided into 3 groups: TwHF treatment group (DT, n = 15), irbesartan treatment group (DI, n = 15), and TwHF combined with irbesartan treatment group (DTI, n = 15)." | 2.78 | [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients]. ( Ma, RX; Zhang, W; Zhao, N, 2013) |
| "133 patients with type 2 diabetic nephropathy (age, 66 ± 8 years; 76% men) from 17 centers in Spain." | 2.78 | Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. ( Barrio, V; Cachofeiro, V; de Vinuesa, SG; Fernandez Juarez, G; Fernández Vega, F; Goicoechea, M; Gutierrez, E; Luño, J; Nieto, J; Praga, M; Tato, A, 2013) |
| "Treatment of patients with type 2 diabetes with Irbesartan decreased urinary excretion of MG-H1, G-H1 and 3-NT, which may result from decreased exposure to these AGEs." | 2.77 | Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. ( Adaikalakoteswari, A; Parving, HH; Rabbani, N; Rossing, K; Rossing, P; Tarnow, L; Thornalley, PJ, 2012) |
| "A total of 40 normotensive type 2 diabetes patients (mean age 55." | 2.73 | Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes. ( Cetinkalp, SS; Erdogan, MA; Karadeniz, MM; Ozgen, GA; Yilmaz, CO, 2008) |
| "In patients with diabetic nephropathy, urinary mRNA expression of podocyte markers correlated with baseline renal function." | 2.73 | Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. ( Chow, KM; Kwan, BC; Lai, FM; Lai, KB; Li, PK; Szeto, CC; Wang, G, 2008) |
| " The article also discusses the methods for preparation of irbesartan, its physical-chemical properties, analytical methods for its determination, pharmacological-toxicological properties, and dosing information." | 2.72 | Irbesartan (a comprehensive profile). ( Al-Kahtani, HM; Alanazi, Z; Bakheit, AH; Darwish, HW; Darwish, IA, 2021) |
| "The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause." | 2.71 | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003) |
| "All participants had baseline diabetic nephropathy, overt proteinuria, and hypertension and were recruited between 1996 and 1999." | 2.71 | Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2005) |
| "During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI)." | 2.71 | Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. ( Aguilar, D; Berl, T; Gans, DJ; Goldhaber, SZ; Levey, AS; Lewis, EJ; Lewis, JB; Pfeffer, MA; Porush, JG; Rouleau, JL, 2004) |
| "Ultrahigh dosing of irbesartan (900 mg once daily) is generally safe and offers additional renoprotection independent of changes in systemic blood pressure and GFR in comparison to the currently recommended dose of 300 mg." | 2.71 | Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. ( Boomsma, F; Jensen, BR; Parving, HH; Rossing, K; Schjoedt, KJ, 2005) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world." | 2.69 | The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. ( Anzalone, DA; Atkins, RC; Clarke, WR; Hunsicker, LG; Lewis, EJ; Ritz, E; Rodby, RA; Rohde, RD, 2000) |
| " It is believed that piperazine ferulate (PF) combined with irbesartan could result in an improved efficacy in the treatment of DN." | 2.66 | Therapeutic Efficacy of Piperazine Ferulate Combined With Irbesartan in Diabetic Nephropathy: A Systematic Review and Meta-analysis. ( Li, B; Li, D; Liu, R; Peng, LX; Zeng, N, 2020) |
| "Irbesartan reduces left ventricular hypertrophy and increases probability of maintenance of sinus rhythm after cardioversion of atrial fibrillation." | 2.48 | [Irbesartan in clinical practice]. ( Malishevskiĭ, MV, 2012) |
| "Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide." | 2.45 | Rational of the use of aliskiren in hypertension and beyond. ( Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D, 2009) |
| "Hypertension is an important risk factor for cardiovascular disease (CVD), particularly in patients with comorbid obesity, diabetes, metabolic disease, or end-organ damage." | 2.44 | The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy. ( Ruilope, LM; Segura, J, 2008) |
| "The mean +/- SD cumulative incidence of ESRD was reduced by 8." | 2.44 | Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. ( Palmer, AJ; Ray, JA; Valentine, WJ, 2007) |
| "Mean time to onset of ESRD was 8." | 2.43 | Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. ( Cordonnier, DJ; Gabriel, S; Palmer, AJ; Roze, S; Tucker, DM; Valentine, WJ, 2005) |
| "The Irbesartan Diabetic Nephropathy Trial showed that irbesartan is more effective than traditional antihypertensive therapies in reducing the progression toward ESRD in patients with type 2 diabetes and overt nephropathy regardless of changes in BP." | 2.43 | Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. ( Deferrari, G; Parodi, D; Ratto, E; Ravera, M; Vettoretti, S, 2005) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| "Proteinuria was reduced on average by 33% in the irbesartan group as compared with 6% in the amlodipine group and 10% in the placebo group." | 2.42 | Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003) |
| "Type 2 diabetes is increasing globally and is a major cause of conditions such as cardiovascular disease, retinopathy and nephropathy." | 2.42 | What is the impact of PRIME on real-life diabetic nephropathy? ( Ruilope, LM, 2004) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 2.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy." | 2.41 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002) |
| "Irbesartan and creatinine clearance in NIDDM patients." | 2.40 | Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system. ( Hollenberg, NK, 1997) |
| "Treatment with dapagliflozin, irbesartan, and especially their combination, produced significant reduction in albuminuria, improved renal function parameters, increased sRAGE level and improved inflammatory and oxidative markers, together with amelioration of renal histopathological changes." | 1.48 | Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. ( Abdel-Wahab, AF; Al-Harizy, RM; Bamagous, GA; ElSawy, NA; Ghamdi, SSA; Ibrahim, IA; Shahzad, N, 2018) |
| "HKC was administered to the diabetic nephropathy rats at three different doses: high dose HKC (300mg/kg/d); middle dose HKC (175mg/kg/d); and low dose HKC (75mg/kg/d)." | 1.43 | Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats. ( Ge, J; Miao, JJ; Sun, XY; Yu, JY, 2016) |
| "Bilirubin was inversely associated with the renal end point in RENAAL independent of age, sex, race, BMI, smoking, total cholesterol, diastolic blood pressure, HbA1c, treatment, estimated glomerular filtration rate, albumin-to-creatinine ratio, and AST." | 1.40 | Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. ( Bakker, SJ; Cooper, ME; de Zeeuw, D; Deetman, PE; Lambers Heerspink, HJ; Lewis, JB; Navis, G; Riphagen, IJ, 2014) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| "T2DM rats were induced by fed with high-sucrose-high-fat diet combined with a low dose of streptozocin." | 1.38 | [Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model]. ( Li, YS; Liu, LQ; Ma, RX; Xu, Y; Zhang, J, 2012) |
| "Cumulative incidence of ESRD, time to onset of ESRD, life expectancy (LE), quality-adjusted life years (QALY) and costs were projected over 25 years for 1,000 simulated patients, from a third party payer perspective." | 1.33 | [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy]. ( Lehnert, H; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S; Valentine, WJ, 2006) |
| "Treating patients with hypertension, type 2 diabetes and overt nephropathy using irbesartan was both cost- and life-saving compared to amlodipine and control in the Spanish setting." | 1.32 | [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective]. ( Annemans, L; de Alvaro, F; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| "This epidemic growth in ESRD has led to skyrocketing utilization of health care resources." | 1.32 | Pharmacoeconomic challenges in the management of diabetic nephropathy. ( Rodby, RA, 2004) |
| "Treating patients with hypertension, type 2 diabetes and overt nephropathy using irbesartan was both cost- and life-saving compared with amlodipine and control." | 1.32 | An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. ( Annemans, L; Cordonnier, DJ; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2003) |
| "As obesity is a common finding in diabetic individuals, and obesity has been linked to an increase in plasma angiotensinogen levels, we enrolled diabetic subjects with a wide range of body mass index (BMI) for this study." | 1.31 | Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. ( Fisher, ND; Hollenberg, NK; Laffel, LM; Lansang, MC; Osei, SY; Price, DA, 2002) |
| "Patients with Type 2 diabetes and nephropathy should receive either an AT(1) antagonist or the angiotensin converting enzyme inhibitor ramipril to ensure renoprotection." | 1.31 | Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy. ( Doggrell, SA, 2002) |
| "Although diabetic nephropathy is often a low renin state, the renin system appears to be implicated in its pathogenesis." | 1.30 | The paradox of the low-renin state in diabetic nephropathy. ( De'Oliveira, JM; Fisher, ND; Gordon, M; Hollenberg, NK; Laffel, LM; Passan, DR; Porter, LE; Price, DA; Williams, GH, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (3.36) | 18.2507 |
| 2000's | 105 (70.47) | 29.6817 |
| 2010's | 33 (22.15) | 24.3611 |
| 2020's | 6 (4.03) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, J | 1 |
| Liang, Z | 1 |
| Zhao, F | 1 |
| Liu, X | 1 |
| Ma, N | 1 |
| Zhao, J | 1 |
| Tostivint, I | 1 |
| Xu, L | 1 |
| Huang, J | 1 |
| Gambotti, L | 1 |
| Boffa, JJ | 1 |
| Yang, M | 1 |
| Wang, L | 1 |
| Sun, Z | 1 |
| Chen, X | 2 |
| Liou-Schischmanoff, A | 1 |
| Baumelou, A | 1 |
| Ma, T | 1 |
| Lu, G | 1 |
| Li, L | 1 |
| Chen, D | 1 |
| Piéroni, L | 1 |
| Liu, B | 1 |
| Qin, X | 1 |
| He, W | 1 |
| Wang, Y | 2 |
| Gu, HF | 1 |
| Sun, W | 1 |
| Zhang, FP | 1 |
| Jiang, X | 1 |
| Li, D | 1 |
| Li, B | 1 |
| Peng, LX | 1 |
| Liu, R | 1 |
| Zeng, N | 1 |
| Fang, LN | 1 |
| Zhong, S | 1 |
| Huang, LJ | 1 |
| Lu, B | 1 |
| Shen, LW | 1 |
| Tang, FY | 1 |
| Sun, HP | 1 |
| Zhang, L | 1 |
| Darwish, IA | 1 |
| Darwish, HW | 1 |
| Bakheit, AH | 1 |
| Al-Kahtani, HM | 1 |
| Alanazi, Z | 1 |
| Hsu, FY | 1 |
| Lin, FJ | 1 |
| Ou, HT | 1 |
| Huang, SH | 1 |
| Wang, CC | 1 |
| Zhao, XM | 1 |
| Zhang, Y | 1 |
| He, XH | 1 |
| Chen, HD | 1 |
| Wang, ZF | 1 |
| Guo, J | 1 |
| Wang, XM | 1 |
| Gao, ZZ | 1 |
| Wang, JP | 1 |
| Liu, W | 1 |
| Zhao, LH | 1 |
| Tong, XL | 1 |
| Abdel-Wahab, AF | 1 |
| Bamagous, GA | 1 |
| Al-Harizy, RM | 1 |
| ElSawy, NA | 1 |
| Shahzad, N | 1 |
| Ibrahim, IA | 1 |
| Ghamdi, SSA | 1 |
| Chen, Y | 1 |
| Liu, P | 1 |
| Li, Y | 1 |
| Zhang, F | 1 |
| Zuo, Y | 1 |
| Li, T | 1 |
| Lei, Z | 1 |
| Wang, H | 1 |
| Mu, W | 1 |
| Zhai, J | 1 |
| Xing, D | 1 |
| Miao, S | 1 |
| Wang, J | 1 |
| Deng, Y | 1 |
| Wang, N | 1 |
| Chen, H | 1 |
| Yang, H | 1 |
| He, X | 1 |
| Shang, H | 1 |
| Ma, RX | 2 |
| Zhao, N | 1 |
| Zhang, W | 1 |
| Gialama, F | 1 |
| Maniadakis, N | 1 |
| Hartner, A | 1 |
| Cordasic, N | 1 |
| Klanke, B | 1 |
| Menendez-Castro, C | 1 |
| Veelken, R | 1 |
| Schmieder, RE | 2 |
| Hilgers, KF | 1 |
| Riphagen, IJ | 1 |
| Deetman, PE | 1 |
| Bakker, SJ | 3 |
| Navis, G | 1 |
| Cooper, ME | 4 |
| Lewis, JB | 10 |
| de Zeeuw, D | 8 |
| Lambers Heerspink, HJ | 5 |
| Hull, TD | 1 |
| Agarwal, A | 1 |
| McMullan, CJ | 1 |
| Parving, HH | 13 |
| Dwyer, JP | 1 |
| Forman, JP | 1 |
| Schutte, E | 1 |
| Lutgers, HL | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Gansevoort, RT | 1 |
| Felix Kröpelin, T | 1 |
| Holtkamp, FA | 2 |
| Packham, DK | 1 |
| L Heerspink, HJ | 1 |
| Chen, XW | 1 |
| Du, XY | 1 |
| Wang, YX | 1 |
| Wang, JC | 1 |
| Liu, WT | 1 |
| Chen, WJ | 1 |
| Li, HY | 1 |
| Peng, FF | 1 |
| Xu, ZZ | 2 |
| Niu, HX | 2 |
| Long, HB | 3 |
| Ge, J | 1 |
| Miao, JJ | 1 |
| Sun, XY | 1 |
| Yu, JY | 1 |
| Tunçdemir, M | 2 |
| Öztürk, M | 2 |
| Vieitez, P | 2 |
| Gómez, O | 2 |
| Uceda, ER | 1 |
| Vera, ME | 1 |
| Molina-Holgado, E | 1 |
| Persson, F | 1 |
| Rossing, P | 3 |
| Hovind, P | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Tarnow, L | 2 |
| Croom, KF | 2 |
| Plosker, GL | 1 |
| Ruilope, LM | 5 |
| Segura, J | 3 |
| Cetinkalp, SS | 1 |
| Karadeniz, MM | 1 |
| Erdogan, MA | 1 |
| Ozgen, GA | 1 |
| Yilmaz, CO | 1 |
| Sen, S | 2 |
| Saniye, S | 1 |
| Kanter, M | 2 |
| Mehmet, K | 1 |
| Ustundag, S | 2 |
| Sedat, U | 1 |
| Aktas, C | 2 |
| Cevat, A | 1 |
| Dogutan, H | 1 |
| Yalcin, O | 1 |
| Omer, Y | 1 |
| Ren, X | 1 |
| Guan, G | 1 |
| Liu, G | 2 |
| Chen, HB | 1 |
| Lu, JX | 1 |
| Li, Q | 2 |
| Bao, YQ | 1 |
| Tang, JL | 2 |
| Lu, HJ | 1 |
| Xiang, KS | 1 |
| Jia, WP | 1 |
| Bramlage, P | 4 |
| Durand-Zaleski, I | 1 |
| Desai, N | 1 |
| Pirk, O | 1 |
| Hacker, C | 1 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Westermann, D | 1 |
| Savvatis, K | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Schindler, C | 1 |
| Li, XY | 1 |
| Zhou, WD | 2 |
| He, JH | 1 |
| Zhong, J | 2 |
| Wei, LB | 2 |
| Donmez, S | 1 |
| Erboga, M | 1 |
| Andersen, S | 5 |
| Mischak, H | 1 |
| Zürbig, P | 1 |
| Dai, HY | 1 |
| Zheng, M | 1 |
| Tang, RN | 1 |
| Ni, J | 1 |
| Ma, KL | 2 |
| Liu, BC | 3 |
| Rabbani, N | 1 |
| Adaikalakoteswari, A | 1 |
| Rossing, K | 4 |
| Thornalley, PJ | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 2 |
| Berl, T | 6 |
| Remuzzi, G | 2 |
| Packham, D | 1 |
| Zhu, Y | 1 |
| Shen, J | 1 |
| Hu, YY | 1 |
| Liu, S | 1 |
| Ishibashi, Y | 1 |
| Matsui, T | 1 |
| Takeuchi, M | 1 |
| Yamagishi, S | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 2 |
| Smink, PA | 1 |
| Ros-Ruiz, S | 1 |
| Aranda-Lara, P | 1 |
| Fernández, JC | 1 |
| Martínez-Esteban, MD | 1 |
| Jironda, C | 1 |
| Hidalgo, P | 1 |
| Hernández-Marrero, D | 1 |
| Xu, Y | 1 |
| Zhang, J | 1 |
| Li, YS | 1 |
| Liu, LQ | 1 |
| Wang, FL | 1 |
| Chen, ZQ | 1 |
| Wang, YH | 1 |
| Fernandez Juarez, G | 1 |
| Luño, J | 1 |
| Barrio, V | 1 |
| de Vinuesa, SG | 1 |
| Praga, M | 1 |
| Goicoechea, M | 1 |
| Cachofeiro, V | 1 |
| Nieto, J | 1 |
| Fernández Vega, F | 1 |
| Tato, A | 1 |
| Gutierrez, E | 1 |
| Malishevskiĭ, MV | 1 |
| Bonnet, F | 1 |
| Candido, R | 1 |
| Carey, RM | 1 |
| Casley, D | 1 |
| Russo, LM | 1 |
| Osicka, TM | 1 |
| Cao, Z | 1 |
| Zanella, MT | 1 |
| Ribeiro, AB | 2 |
| Price, DA | 3 |
| Lansang, MC | 1 |
| Osei, SY | 1 |
| Fisher, ND | 2 |
| Laffel, LM | 2 |
| Hollenberg, NK | 4 |
| Suzuki, H | 1 |
| Sasso, FC | 1 |
| Carbonara, O | 1 |
| Persico, M | 1 |
| Iafusco, D | 1 |
| Salvatore, T | 1 |
| D'Ambrosio, R | 1 |
| Torella, R | 1 |
| Cozzolino, D | 1 |
| Haneda, M | 1 |
| Sugimoto, T | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Chen, Q | 1 |
| Luo, DD | 2 |
| Sun, J | 2 |
| Phillips, AO | 1 |
| Ruan, XZ | 2 |
| Liu, NF | 1 |
| Eberhard, R | 1 |
| Dikow, R | 1 |
| Hunsicker, LG | 10 |
| Pfeffer, MA | 3 |
| Porush, JG | 3 |
| Rouleau, JL | 3 |
| Drury, PL | 2 |
| Esmatjes, E | 3 |
| Hricik, D | 2 |
| Parikh, CR | 1 |
| Raz, I | 3 |
| Vanhille, P | 2 |
| Wiegmann, TB | 4 |
| Wolfe, BM | 2 |
| Locatelli, F | 4 |
| Goldhaber, SZ | 3 |
| Lewis, EJ | 11 |
| Jacobsen, P | 2 |
| Jensen, BR | 2 |
| Biesenbach, G | 1 |
| Janko, O | 1 |
| Mohanram, A | 1 |
| Toto, RD | 1 |
| Ito, S | 1 |
| Sidorenko, BA | 2 |
| Preobrazhenskiĭ, DV | 2 |
| Stetsenko, TM | 2 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Rodby, RA | 13 |
| Chiou, CF | 1 |
| Borenstein, J | 1 |
| Smitten, A | 1 |
| Sengupta, N | 1 |
| Palmer, AJ | 12 |
| Roze, S | 10 |
| Annemans, L | 7 |
| Simon, TA | 1 |
| Chen, RS | 1 |
| Lamotte, M | 5 |
| Cordonnier, DJ | 3 |
| González-Albarrán, O | 1 |
| Ruiz, E | 1 |
| García-Robles, R | 1 |
| Lehnert, H | 5 |
| Pittrow, D | 2 |
| Kirch, W | 2 |
| Ritz, E | 5 |
| Coyle, D | 2 |
| Foreman, BH | 1 |
| Chambliss, ML | 1 |
| Soplevenko, AV | 1 |
| Ivanova, NA | 1 |
| Curran, MP | 1 |
| Goa, KL | 1 |
| Perry, CM | 1 |
| Kaiser, T | 1 |
| Florack, C | 1 |
| Sawicki, PT | 1 |
| Aguilar, D | 1 |
| Gans, DJ | 1 |
| Levey, AS | 1 |
| Lapuerta, P | 2 |
| Chen, R | 3 |
| Gabriel, S | 3 |
| Carita, P | 2 |
| de Alvaro, F | 3 |
| Schunkert, H | 1 |
| Atkins, RC | 5 |
| Braden, G | 2 |
| de Crespigny, PJ | 1 |
| DeFerrari, G | 4 |
| Drury, P | 2 |
| Llewelyn, DE | 1 |
| Garcia-Puig, J | 1 |
| Briganti, EM | 1 |
| Champion de Crespigny, PJ | 1 |
| Leehey, DJ | 1 |
| Isreb, MA | 1 |
| Marcic, S | 1 |
| Singh, AK | 1 |
| Singh, R | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Tucker, DM | 2 |
| Valentine, WJ | 5 |
| Shlipak, M | 1 |
| Pohl, M | 1 |
| Ravera, M | 1 |
| Ratto, E | 1 |
| Vettoretti, S | 1 |
| Parodi, D | 1 |
| Friedman, AN | 2 |
| Selhub, J | 2 |
| Bostom, AG | 2 |
| García-Donaire, JA | 1 |
| Salcedo-Alejos, M | 1 |
| Banda-Espinoza, F | 1 |
| Rodríguez-Morán, M | 1 |
| Guerrero-Romero, F | 1 |
| Schjoedt, KJ | 1 |
| Boomsma, F | 1 |
| Pohl, MA | 2 |
| Blumenthal, S | 1 |
| Eisner, G | 1 |
| Gilbert, RE | 2 |
| de Faria, JB | 1 |
| Mangili, R | 1 |
| Moore, J | 1 |
| Reisin, E | 1 |
| Schernthaner, G | 1 |
| Spitalewitz, S | 1 |
| Tindall, H | 1 |
| Matos, JP | 1 |
| de Lourdes Rodrigues, M | 1 |
| Ismerim, VL | 1 |
| Boasquevisque, EM | 1 |
| Genelhu, V | 1 |
| Francischetti, EA | 1 |
| Krekler, M | 1 |
| Burnier, M | 3 |
| Zanchi, A | 1 |
| Janiak, P | 1 |
| Bidouard, JP | 1 |
| Cadrouvele, C | 1 |
| Poirier, B | 1 |
| Gouraud, L | 1 |
| Grataloup, Y | 1 |
| Pierre, F | 1 |
| Bruneval, P | 1 |
| O'Connor, SE | 1 |
| Herbert, JM | 1 |
| Frei, A | 2 |
| Hess, B | 2 |
| Gavras, H | 1 |
| Ray, JA | 3 |
| Spinas, GA | 1 |
| Brändle, M | 1 |
| Ruggenenti, P | 1 |
| Laville, M | 1 |
| Rodby, R | 1 |
| Soroka, S | 1 |
| Levin, A | 1 |
| Muirhead, N | 1 |
| de Cotret, PR | 1 |
| Palmer, A | 1 |
| Wang, G | 1 |
| Lai, FM | 1 |
| Lai, KB | 1 |
| Chow, KM | 1 |
| Kwan, BC | 1 |
| Li, PK | 1 |
| Szeto, CC | 1 |
| Busch, M | 1 |
| Franke, S | 1 |
| Wolf, G | 1 |
| Rohde, RD | 2 |
| Stein, G | 1 |
| O'Donnell, MP | 1 |
| Crary, GS | 1 |
| Oda, H | 1 |
| Kasiske, BL | 1 |
| Powell, JR | 1 |
| Keane, WF | 1 |
| Man in't Veld, AJ | 1 |
| Porter, LE | 1 |
| Gordon, M | 1 |
| De'Oliveira, JM | 1 |
| Passan, DR | 1 |
| Williams, GH | 1 |
| Clarke, WR | 2 |
| Anzalone, DA | 1 |
| Descombes, E | 1 |
| Fellay, G | 1 |
| Bold, KO | 1 |
| Rohde, R | 1 |
| Bröchner-Mortensen, J | 1 |
| Gomis, R | 2 |
| Arner, P | 3 |
| Bloomgarden, ZT | 1 |
| Brøchner-Mortensen, J | 1 |
| Kurtzman, NA | 1 |
| Jerums, G | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Walser, M | 1 |
| Ceriello, A | 1 |
| Motz, E | 1 |
| Doggrell, SA | 1 |
| Hansen, BV | 1 |
| Studney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-controlled, Multi-center Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease[NCT03016832] | Early Phase 1 | 414 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)[NCT00317915] | Phase 3 | 0 participants | Interventional | Completed | |||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| [NCT00021918] | 0 participants | Observational | 2001-04-30 | Completed | |||
| Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria[NCT00320879] | Phase 4 | 52 participants | Interventional | 2003-09-30 | Completed | ||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy[NCT01300273] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-02-28 | Active, not recruiting | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
41 reviews available for avapro and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Therapeutic Efficacy of Piperazine Ferulate Combined With Irbesartan in Diabetic Nephropathy: A Systematic Review and Meta-analysis.
Topics: Adult; Aged; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Humans; Irbesartan; Middle Age | 2020 |
Irbesartan (a comprehensive profile).
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2021 |
Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Diabetic Nephropathies; Drug Therapy, Combina | 2019 |
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2013 |
Irbesartan: a review of its use in hypertension and diabetic nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabe | 2008 |
The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases; Causality; Cer | 2008 |
The value of irbesartan in the management of hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressur | 2009 |
Rational of the use of aliskiren in hypertension and beyond.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl C | 2009 |
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
Topics: Administration, Oral; Angiotensin II; Antihypertensive Agents; Biological Availability; Biphenyl Com | 2010 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
[Irbesartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2012 |
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; | 2002 |
[Diabetic nephropathy].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2002 |
[Evidence based treatment of diabetic nephropathy].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseas | 2002 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
Angiotensin receptor blockers in diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabe | 2001 |
Outcome studies in diabetic nephropathy.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2003 |
[Antihypertensive therapy in renal dysfunction].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diab | 2004 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bipheny | 2004 |
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds | 2004 |
What is the impact of PRIME on real-life diabetic nephropathy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mell | 2004 |
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetic Nephropathies; Humans; Irbesar | 2004 |
Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.
Topics: Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabetic Nephropathies; Economic | 2005 |
Diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Glucose; Captopril; Diabetic Nep | 2004 |
Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
Topics: Biphenyl Compounds; Cause of Death; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double | 2005 |
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2005 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds | 2006 |
Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
Topics: Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Computer Simulation; Costs and Cost Ana | 2007 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 1997 |
Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Contr | 1997 |
[Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Melli | 2001 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
39 trials available for avapro and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Efficacy of Combined Abelmoschus manihot and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial.
Topics: Abelmoschus; Albuminuria; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dou | 2022 |
The efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy.
Topics: Canagliflozin; Diabetic Nephropathies; Humans; Irbesartan; Treatment Outcome | 2022 |
Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Creatinine; Diabetic Nephro | 2018 |
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2018 |
The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Com | 2013 |
[The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients].
Topics: Aged; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drugs, Chinese Herbal; | 2013 |
Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Cardiovascular Di | 2014 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
Topics: Adult; Aged; Albuminuria; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephro | 2008 |
Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Diabetes M | 2008 |
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
Topics: Albuminuria; Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bendrofl | 2012 |
An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular System; Data Inter | 2012 |
High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetic Nephropathies; Fe | 2012 |
[Clinical observation of treating early diabetic nephropathy by qi supplementing, yin nourishing, blood stasis dispersing, collateral dredging recipe].
Topics: Adult; Aged; Biphenyl Compounds; Diabetic Nephropathies; Drugs, Chinese Herbal; Female; Humans; Irbe | 2012 |
Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 2013 |
Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
Topics: Adult; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Diabetes Mellit | 2002 |
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Comp | 2003 |
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diab | 2004 |
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy.
Topics: Adult; Aged; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropa | 2004 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetic Angiopathies; Diabet | 2004 |
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nep | 2005 |
C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biomarkers; Biphenyl Compounds; C-R | 2005 |
Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Child; Creatinine; Diabetes | 2005 |
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood P | 2005 |
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Di | 2005 |
Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Cardiovascular Syst | 2005 |
Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compou | 2005 |
Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Co | 2008 |
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Biphen | 2008 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2000 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compou | 2001 |
A clinical trial in type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block | 2001 |
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Topics: Adult; Aged; Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Cardiovascula | 2001 |
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 2002 |
70 other studies available for avapro and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Triptolide inhibits oxidative stress and inflammation via the microRNA-155-5p/brain-derived neurotrophic factor to reduce podocyte injury in mice with diabetic nephropathy.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Diabetes Mellitus; Diabetic Nephropathies; Di | 2022 |
Protective Effect of Irbesartan by Inhibiting ANGPTL2 Expression in Diabetic Kidney Disease.
Topics: Angiopoietin-Like Protein 2; Angiopoietin-like Proteins; Animals; Cells, Cultured; Diabetic Nephropa | 2020 |
Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 2017 |
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetic | 2018 |
Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biphenyl Compounds; Blood Glucose; Bloo | 2014 |
Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Typ | 2014 |
Bilirubin: a potential biomarker and therapeutic target for diabetic nephropathy.
Topics: Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Ir | 2014 |
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, T | 2016 |
Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blotting, Western; Diabetes Mellitus, Type 2; | 2016 |
Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
Topics: Abelmoschus; Administration, Oral; Albuminuria; Animals; Biphenyl Compounds; Capsules; Diabetes Mell | 2016 |
Regulation of the Ku70 and apoptosis-related proteins in experimental diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosi | 2016 |
Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, West | 2008 |
Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl | 2008 |
Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Connect | 2009 |
The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cross-Sectional Studies; Diabetes | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
[Effects of irbesartan on renal advanced glycation end products and their receptor in rats with early diabetic nephropathy].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Diabetes Mellitus, Experimenta | 2009 |
Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats.
Topics: Animals; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Immuno | 2010 |
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; | 2010 |
The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Biphenyl Compounds | 2011 |
Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; | 2011 |
[Transforming growth factor-β1 regulates renal α3 and β1 integrin expressions in diabetic rats: a new insight into the renoprotective effect of irbesartan].
Topics: Animals; Biphenyl Compounds; Diabetes Mellitus; Diabetic Nephropathies; Integrin alpha3; Integrin be | 2011 |
Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biphenyl Compounds; Cattle; Cells, Cult | 2012 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
[Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model].
Topics: Animals; Biphenyl Compounds; Bone Morphogenetic Protein 7; Connective Tissue Growth Factor; Diabetes | 2012 |
Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diab | 2002 |
Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan.
Topics: Adult; Angiotensin I; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Body Mas | 2002 |
Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Connective T | 2003 |
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
The true overall mortality of unselected nephropathic type 2 diabetic patients with mild to moderate renal insufficiency.
Topics: Antihypertensive Agents; Biphenyl Compounds; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2003 |
[Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes | 2003 |
[Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basement Membrane; Biphenyl Compounds; Diabetes Me | 2003 |
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabete | 2003 |
An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Topics: Adult; Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Belgium; Biphenyl Compounds; Ca | 2003 |
Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats).
Topics: Albuminuria; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus | 2003 |
[Prospective treatment study of irbesartan. Diabetic kidneys regain function].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2003 |
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M | 2004 |
Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetic Nephrop | 2004 |
[Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephro | 2004 |
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patien
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Chann | 2004 |
[Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
Topics: Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabe | 2004 |
Pharmacoeconomic challenges in the management of diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Costs and Cos | 2004 |
[A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; | 2004 |
[Test for microalbuminuria. Life saving for hypertensive and diabetic patients].
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Coronary Artery Disease; Diabetic Nephropa | 2004 |
Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cell Culture Techniques | 2005 |
[Therapeutic implications of ACE-gene polymorphism].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetic Nephr | 2005 |
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2006 |
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca | 2006 |
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2006 |
[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Computer Simulation; Costs and Cost Ana | 2006 |
What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Di | 2006 |
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cost-Benefit Analysis; Dia | 2006 |
[Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Desmin; Diabetes Mellitus, Exp | 2007 |
Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Canada; Cost-Benefit Analysis; Diabetes | 2007 |
Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Co | 1997 |
The paradox of the low-renin state in diabetic nephropathy.
Topics: Adult; Angiotensinogen; Biphenyl Compounds; Blood Pressure; Body Mass Index; Diabetic Nephropathies; | 1999 |
End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Captopril; Diab | 2000 |
[Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2001 |
[Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2001 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
Drug companies should not have the final say in the design of clinical trials.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2001 |
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2001 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
[Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].
Topics: Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nep | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
[Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
Topics: Albuminuria; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2002 |